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The discovery and application of CRISPR/Cas9 technology
for genome editing has greatly accelerated targetedmutagenesis
in a variety of organisms. CRISPR/Cas9-mediated site-specific
cleavage is typically exploited for the generation of insertions or
deletions (indels) after aberrant dsDNA repair via the endoge-
nous non-homology end-joining (NHEJ) pathway or, alterna-
tively, for enhancing homology-directed repair to facilitate the
generation of a specific mutation (or “knock-in”). However,
there is a need for efficient cellular assays that can measure
Cas9/guide RNA activity. Reliable methods for enriching and
identifying desiredmutants are also lacking. Here we describe a
method using the Piggybac transposon for stable genomic inte-
gration of an H2B-GFP reporter or a hygromycin resistance
gene for assaying Cas9 target cleavage and homology-directed
repair. TheH2B-GFP fusionprotein provides increased stability
and an obvious pattern of nuclear localization. This method,
called SRIRACCHA (i.e. a stable, but reversible, integrated
reporter for assaying CRISPR/Cas-stimulated HDR activity),
enables the enrichment ofmutants via selection ofGFP-positive
or hygromycin-resistant mammalian cells (immortalized or
non-immortalized) as a surrogate for the modification of the
endogenous target site. Currently available hyperactive Piggybac
transposase mutants allow both delivery and removal of the
surrogate reporters, with minimal risk of generating undesir-
able mutations. This assay permits rapid screening for efficient
guide RNAs and the accelerated identification of mutant clones
and is applicable tomany cell types.We foresee the utility of this
approach in contexts in which the maintenance of genomic
integrity is essential, for example, when engineering cells for
therapeutic purposes.
CRISPR/Cas9 is an RNA-guided endonuclease (RGEN)2
that was discovered as part of an immune defense mecha-
nism in bacteria whereby foreign DNA, e.g. from pathogenic
phage, is cleaved by a specialized nuclease using RNA mole-
cules (gRNAs) to dictate sequence specificity, thus preventing
horizontal gene transfer (1). The adoption of the CRISPR/Cas9
system from Staphylococcus pyogenes, typically employing a
single protein SpCas9 and a single synthetic gRNA, has brought
about widespread implementation of this powerful site-spe-
cific RGEN for generating knockouts or precise gene editing
in a wide variety of eukaryotic cell types, e.g. in plants, inver-
tebrates, and mammals, including human cells.
Since the description of the CRISPR/Cas9 technology in
eukaryotes, it has quickly gained popularity over other similar
approaches such as the transcription activator-like effector
nuclease (TALEN). The popularity of RGENs is due to their
simplicity of design and high efficiency in a variety of mamma-
lian cell types and embryos for both somatic and germ line
mutagenesis. Specificity of this RGEN system is conferred by a
20-nucleotide region of the gRNA, which targets the Cas9
nuclease to complementary dsDNA sequences (i.e. protospac-
ers) immediately followed by a protospacer adjacent motif
(PAM), which for SpCas9 systems is NGG, and is required for
Cas9 recognition and cleavage. Although both RGEN and
TALEN (transcription activator-like effector nuclease) tech-
niques harness nonspecific DNA endonucleases to generate
double-stranded breaks (DSBs) (with both systems able to
achieve high efficiency), RGEN use has accelerated because of
the ease of generating gRNAs using standard cloning tech-
niques and in vitro transcription or RNA polymerase III pro-
moters. However, CRISPR/Cas9 RGENs have the potential for
off-target effects (2–5), and therefore, onemust typically screen
many gRNAs to select for both high efficiency and high speci-
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ficity. Alternatively, higher specificity can be achieved through
modified RGEN approaches, such as the paired nickase
approachwith theCas9D10Amutant and two gRNAs, which has
greatly improved fidelity of RGENs for the generation of DSBs
without a substantial loss of efficiency (3, 5); however, the
paired nickase approach still requires the preselection of highly
efficient pairs of gRNAs.
The simple, flexible, and highly efficient nature of
CRISPR/Cas9 propels this RGEN system to become the most
widely adopted technique for gene editing. The potential of
the CRISPR/Cas9 system has been demonstrated through suc-
cessful reverse genetic approaches in cells andwhole organisms
(6–9), multiplexed gene editing for simultaneously targeting
multiple genes (7, 8, 10, 11), genome-wide genetic screens (12–
20), and also for gene therapy in human cells (21–24). However,
the practical application of CRISPR/Cas9 for generating knock-
outs (through the generation of DSBs and deletions) or precise
gene editing (for knock-ins via homology directed repair with a
donor template) still requires assayingmultiple gRNAs for opti-
mal activity/specificity and screening many cellular clones to
identify the desired mutation.
The Piggybac (PB) transposon is a cut-and-paste mobile
DNA element originally isolated from Trichoplusia ni and has
undergone successive modifications through both codon opti-
mization and directed evolution to generate one of the most
highly active transposons for use in mammalian cells (25, 26).
Typical applications exploit PB for stable integration of foreign
DNA into the genome as a safer and easier alternative to retro-
viral vectors in cell types that can be transfected with low or
modest efficiency. The PB transposon acts by precise mobiliza-
tion into TTAA sequences, with a modest preference for tran-
scriptional units (27). PB can mobilize multiple copies of a
transposon into the genome with high efficiency (28) and can
also mobilize very large pieces of DNA (up to 100 kb) (29).
Another highly unique and practical property of the PB DNA
transposon is the ability to both mobilize and remove inte-
grated transposons using the PB transposase (PBase). With the
development of an excision-only (ExcInt) mutant PBase
(30), transposons can now be removed without the risk of rein-
tegration. Lastly, one key advantage of PB is its “footprint-free”
mobilization whereby sequence integrity around the TTAA
integration site is preserved after excision of the PB transposon
(28, 31–34).
Despite the success of RGENs for gene knock-out or editing,
their performance is largely determined by the quality and
specificity of guide RNAs. In the nucleus, chromatin accessibil-
ity, nuclease cleavage efficiency, and successful repair through
NHEJ or HDR likely affect the successful generation of desired
mutations. Examining site-specific nuclease activity in cells
after the introduction of RGEN components is possible using
Surveyor or T7 endonuclease 1 (T7E1). These mismatch
detection enzymes cleave bulges in DNA heteroduplexes con-
sisting of wild type and mutated DNA strands (35, 36). How-
ever, these assays are not very sensitive or easily quantifiable,
whereas more quantitative methods, such as high throughput
targeted deep sequencing, can be prohibitively expensive, espe-
cially when assaying large numbers of gRNAs. Our goal here is
to exploit the PB DNA transposon to deliver into the mamma-
lian genome of cultured cells a reporter construct that provides
a read-out of site-specific nuclease cleavage. Through transfec-
tion of a repair “donor” template, reporter expression (H2B-
GFP or a hygromycin resistance gene) is restored throughHDR
after the generation of a DSB. Perhaps most useful of all, puri-
fication of H2B-GFP cells and/or selection of hygromycin-re-
sistant cells enables the enrichment of mutant clones. Further-
more, the properties of the PB transposon enable the seamless
removal of integrated transposons after the selection and char-
acterization of desired mutations at endogenous target loci.
This approach both accelerates gRNA validation and the gen-
eration of desired mutations.
Results
A transposable GFP reporter to assay CRISPR activity
The transposable SRIRACCHA GFP reporter consists of a
CMV-driven puromycin resistance gene followed by a single
cloning site for inserting endonuclease target sequences, a
short polyadenylation signal, and an out-of-frame H2B-
tagged GFP, which lacks a start codon followed by two
chicken hypersensitive site IV (HSIV) insulator sequences to
prevent silencing by heterochromatin. A schematic for a
paired nickase (Cas9D10A) target, with two SpCas9 proto-
spacers and PAMs, is shown (Fig. 1A). A donor plasmid is
co-transfected with RGEN components (Cas9 and gRNAs)
to promote repair and gene conversion via HDR. The donor
plasmid contains the puromycin resistance gene linked to
the H2B-GFP open reading frame via a T2A peptide coding
sequence. A typical SRIRACCHA assay with this GFP re-
porter entails co-transfection of all components, including a
plasmid encoding the hyperactive PB transposase (CMV-
hyPBase) and co-transfection with an RFP expression plas-
mid (CMV-tdT) for normalization. Cutting and HDR of the
transposon target yields expression of GFP. Quantification
of GFP-positive cells relative to RFP-positive cells thus pro-
vides a read-out of nuclease activity. To optimize signal to
noise, we titrated transposon, PBase, donor, and gRNA (Fig.
1, B and C). Ratios of 3:1 for transposon:hyPBase and 3:2 for
donor:gRNA were optimal, with an approximate 4-fold
induction in RGEN activity with relatively low background
with this gRNA. These ratios were adopted for subsequent
experiments.
Because genome engineering should ideally exhibit high
fidelity, we tested a strategy using an inducible Cas9 nuclease to
limit the temporal window of nuclease activity. In conjunction
with this, we used the Cas9 nickase (Cas9D10A) for paired nick-
ing of target sites, which has been demonstrated to significantly
improve fidelity (3, 5). The dual nickase approach also gener-
ates larger deletions afterNHEJ (37, 38) andmay bemore useful
for generating null alleles. In our approach 4-hydroxytamoxifen
(4-OH-T) and doxycycline (dox) regulate Cas9D10A expression
and nuclear localization (Fig. 1D). As shown in Fig. 1E, there is
very little nuclease activity in the absence of 4-OH-T and dox
compared with a nonspecific (NS) gRNA using this inducible
SRIRACCHA (iSRIRACCHA) method. Dual control with both
4-OH-T anddox further reduced leaky expression andnuclease
activity compared with either 4-OH-T or dox alone (Fig. 1F).
A Piggybac HDR reporter













We also used iSRIRACCHA tomeasure HDRwith and without
the transposase (Fig. 1E). Without the transposase, the signal
was significantly reduced due to the transient nature of the
episomal plasmid. The use of PB, therefore, amplifies and
extends the lifetime of the signal via stable integration of the
GFP reporter into the genome. The iSRIRACCHAmethod gen-
erated robust inducible signal in bothHeLa andHEK293T cells,
but for unknown reasons the backgroundGFP signal was lower
in HeLa cells (Fig. 1, G and H), and this cell line was used for
subsequent assays.
Figure 1. Optimization of the H2B-GFP SRIRACCHA reporter and use with an inducible Cas9D10A nuclease. A, constituents of the Piggybac target
transposon with an H2B-GFP reporter and schematic of the SRIRACCHA process. The target transposon consists of a CMV-driven puromycin resistance gene,
the target sequence (cloned into a BstEII site), a polyadenylation (pA) signal, an out-of-frame H2B-GFP open reading frame, an additional SV40 pA signal, and
two HSIV core insulator sequences at the 3 end. The Piggybac transposon sequences, including inverted terminal repeats, are represented by two outward
facing arrows that flank the CMV-driven expression cassette. The Let-7 protospacer sequences are highlighted in red, and the PAM is in blue. After transposition
into the genomeby hyPBase and nuclease cutting, the donor plasmid supplies the template for HDR, which restores expression of H2B-GFP via a T2A cleavage
sequence. B, the effects of different ratios of transposon and transposase plasmids (by mass) in HEK293T cells. Cells were transfected with plasmids driving
constitutive expression of the transposase, wild type Cas9, gRNAs, and pCMV-tdT along with the target transposon and donor plasmid. The target and gRNA
sequences are froma site inmouseMirlet7g. Puromycinwas added 48 h after transfection, and expression of GFP and RFPwas analyzed 2 days after puromycin
selection. Signals fromnonspecific (NS) gRNAsor targetinggRNAswere also compared.C, the effects of different ratios of donor plasmid andgRNAplasmid (by
mass) in HEK293T cells. Cells were transfected as in B.D, schematic of plasmids used for Cas9D10A induction (iCas9N)with dox and 4-OH-T. E, inducible Cas9D10A
SRIRACCHA assay in the presence and absence of the Piggybac transposase. HeLa cells were transfected as above using a 3:1 transposon to transposase ratio
and a 3:2 ratio of donor to gRNA but substituting hCas9 with plasmids in D. At 24 h, 500 ng/ml dox and 0.5 M 4-OH-T was added to the transfected cells to
induce Cas9D10A expression for 48 h. Fluorescence was examined 72 h after withdrawing dox and 4-OH-T. F, inducibility of Cas9D10A was compared with dox
and/or 4-OH-T treatment, as transfected in E,with fluorescenceexamined48hafterdrugaddition.GandH, SRIRACCHACas9D10A assay inHeLa (G) andHEK293T
(H) cells. HeLa orHEK293T cellswere transfected and induced as in E, with fluorescence examined 24h (for HeLa) or 48 h (for HEK293T) after drug addition. Error
bars represent S.E. of a representative experiment performed in triplicate (and replicated in a total of 2–3 experiments), where Student’s t test was performed
to determine significance relative to vehicle in E–H, with p 0.05 (*) or p 0.01 (**).
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gRNAswith the highest efficiency were predicted by
SRIRACCHA using Cas9D10A
We next sought to determine whether SRIRACCHA could
distinguish different activities of gRNAs in their ability to gen-
erate insertions or deletions (indels) at endogenous target loci.
We designed gRNAs corresponding to three targets sites in
mouse Smad4, Pten, Trp53, and Apc and assayed activity using
the paired nickase approach and two gRNAs per target (Fig. 2,
A–D) or the wild type Cas9 and a single gRNAper target (Fig. 2,
E–H). One gRNA of each gRNA pair (used for the paired nick-
ase assay) was used for the wild type Cas9 assay. As expected,
varying CRISPR activity was observed with different gRNAs
that target the same gene. The gRNApairs targetingApc exhib-
ited the most variation using the paired nickase with varying
signal to noise ratios, whereas Smad4 exhibited the greatest
variability using the wild type Cas9.
To determine whether the CRISPR/Cas9 nuclease activity
measured by SRIRACCHA corresponds to the cutting fre-
quency of endogenous sites in the genome, we subjected single
gRNAs or gRNA pairs (using wild type Cas9 or the Cas9 nick-
ase) for testing by targeted deep sequencing of nuclease target
sites in the mouse Smad4, Pten, Trp53, and Apc genes after
transfection in mouse N2A cells. This enabled the quantifica-
tion of indels after NHEJ, which is proportional to the cutting
frequency by Cas9. Murine N2A cells were nucleofected with
gRNAs for RGEN cleavage by the wild type or nickase Cas9
nuclease. Nuclease target sites in Smad4, Pten, Trp53, or Apc
were PCR-amplified and subsequently analyzed by Illumina
deep sequencing. As shown in Fig. 2I, when Cas9D10A was used,
the relative NHEJ activity of gRNA pairs targeting each gene
was consistent with the relative -fold change of activity re-
flected by our CRISPR reporter assay, except for two gRNAs
specific for target sites in Trp53. However, in this nickase
experiment, gRNA pairs specific for the Trp53 target site T2
exhibited the highest signal to noise ratio both by deep
sequencing assay and SRIRACCHA. Both assays yielded a sim-
Figure2.UsingSRIRACCHAto test the targetingefficiencyofgRNAs.Pairs of gRNAs targeting threeunique sites in eachofmouse Smad4 (A),Pten (B), Trp53
(C), and Apc (D) genes were assayed by a single transfection of SRIRACCHA H2B-GFP components with the inducible Cas9D10A in HeLa cells. Sequences for
variable regions of each gRNA are shown in Table 1. HeLa cells were transfected and induced as described in Fig. 1E. Fluorescence was quantified 3 days after
drug addition. SRIRACCHA assaywithwild type Cas9was performed to test the efficiency of individual gRNAs against Smad4 (E), Pten (F), Trp53 (G), and Apc (H)
in HeLa cells. One gRNA from each gRNA pair (used in A–D) was assayed with wild type Cas9. I, targeted deep sequencing to test the efficiency of gRNA pairs
or individual gRNAs leading to indels at endogenous target sites. Cells were either transfected with a GFP plasmid, as a negative control, or CRISPR/Cas9 plus
gRNAs. Indels were quantified as representative of NHEJ frequency. Error bars represent S.E. of a representative experiment, performed in triplicate (and
replicated in a total of three experiments). Deep sequencing was performed once for each gRNA. J, bright-field images of wild type mouse enteroids and
CRISPR/CasD10A-mutated enteroids harboring loss-of-function mutations in Pten, Apc, or Smad4 genes.
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ilar trend for Pten gRNAs and Trp53 gRNAs with wild type
Cas9. This was not the case for targeting of Smad4 and Apc
using wild type Cas9. We consistently see greater sensitivity
and signal using Cas9D10A in the SRIRACCHA assay compared
with wild type Cas9. This could possibly reflect enhanced HDR
using the paired nickase.
We thenused theT1 gRNApairs and theCas9D10Anickase to
introduce indels into thePten,Apc, or Smad4 genes inwild type
C57BL/6 (B6) mouse small intestine enteroids. The hCas9D10A
and gRNA constructs were transfected into stem cell-enriched
enteroids as previously described (39). Apc-inactivated en-
teroids were selected with medium lacking R-spondin. Pten-
inactivated enteroids were selected with medium lacking EGF
but containing the epidermal GFR/HER2 inhibitor lapatinib.
And Smad4-inactivated enteroids were selected with medium
lacking noggin. Mutations of Apc and Smad4 in enteroids were
confirmed by targeted deep sequencing, whereas Pten muta-
tions were quantified using the T7E1 assay (data not shown).
Notably, these Apc/ and Smad4/mouse enteroids exhib-
ited similar morphological changes with the reported APC/
and SMAD4/ human intestinal enteroids (40) (Fig. 2J).
SRIRACCHA enabled the enrichment ofmutant cells
The stable property of the SRIRACCHA reporter allows the
identification of cells demonstrating CRISPR/Cas-stimulated
HDR of the H2B-GFP reporter. We suspected that enrichment
of GFP cells, which have undergone HDR after cleavage at the
surrogate/synthetic site, would also enrich for cells containing
indels at the endogenous target site. To confirm this we gener-
ated HeLa and DLD1 cell lines with a stably integrated GFP
Piggybac transposon reporter containing a target site for
NFE2L2 (Fig. 3A, left panel). The puromycin-selected cells were
then transfected with the inducible RGEN nickase (iCas9N)
and gRNA components. Twenty-four hours after transfection,
dox and 4-OH-T were added to induce nuclease expression.
When assayed 3 days after induction, SRIRACCHA reporter
activity was induced 8-fold in HeLa cells and 20-fold in
DLD1 cells (Fig. 3A, right panel). H2B-GFP-positive cells were
also assayed for the presence of indels at endogenous NFE2L2
target sites, revealing a 2–4-fold increase in mutation fre-
quency in H2B-GFP-positive cells relative to unsorted cells
(Fig. 3, B and C).
A SRIRACCHA hygromycin reporter for enrichment ofmutant
clones
Because FACS sorting proved to be a reliable method for
enriching mutant cells, we sought to streamline the selection
process by substituting the H2B-GFP gene with a hygromycin
resistance cassette that lacks a start codon (Fig. 4A). To test the
hygromycin reporter assay, DLD1 cells were transfected with
transposon and CRISPR/Cas9 nickase components. Then, 48 h
after transfection, DLD1 cells were subjected to puromycin
selection or hygromycin selection (Fig. 4B, left panel). After
selection, surviving colonies were counted then lysed for gDNA
isolation and analysis of indel frequency using the T7E1 assay.
Three SRIRACCHA hygromycin reporters corresponding to
the A1CF, RBM47, and NFE2L2 genes were analyzed. After
selection of transfected DLD1 cells, targeting gRNAs yielded
6–12 times as many colonies as non-targeting gRNAs (Fig. 4B,
right panel). By T7E1 assay, the hygromycin-resistant clones
exhibited a higher mutation frequency than puromycin-resist-
ant colonies (Fig. 4, C–E).
SRIRACCHA enrichesmutations in non-transformed and
non-immortalized cells
Using gRNAs specific for mouse/rat Pten (Pten-T1; Fig. 2, F
and I), we used a two-step transfection approach, entailing
selection for stable integration of the transposon reporter (Fig.
4A) before transfection of CRISPR/Cas9 components and
donor plasmid (Fig. 4F) in mouse NIH3T3 (non-transformed)
and rat IEC6 (non-immortalized) cells. After selection, indel
frequencywasmeasuredbyT7E1assay. In these cell lineswe sawa
2–3-fold increase of indel mutations after hygromycin selection
(Fig. 4, G and H). This demonstrates that SRIRACCHA can be
exploited for enriching mutants in multiple cell types, both
non-transformed and non-immortalized.
Enriching for null alleles with SRIRACCHA
To generate knock-out clones in DLD1 and HepG2 cells, we
used a two-step transfection method (Fig. 5A) that yielded
results similar to the two-step transfection approach using the
H2B-GFP reporter (Figs. 3A and 5B). Comparing each transfec-
tion approach, the two-step method yielded more colonies,
whereas relative gRNA efficiencies were similar (Figs. 4B versus
5B). Twelve hygromycin-resistant DLD1 colonies were evalu-
Figure 3. Sorting of GFP-positive cells enriches for mutations of targeted genes. A, left panel, workflow of two-step transfection procedure for targeted
mutagenesis using the SRIRACCHA GFP reporter for analysis and cell sorting. Fluorescence read-out (A, right panel) in HeLa and DLD1 cells following this
procedure. TheNFE2L2 genewas targeted in these experiments. Cells were treatedwith dox and 4-OH-T for 72 h, expanded, and subjected to FACS.Mutagen-
esis was determined by T7E1 assays of genomic DNA from unsorted or GFP-sorted HeLa (B) or DLD1 (C) cells. NS denotes nonspecific gRNA, and T denotes
gRNAs specific for NFE2L2. Indel frequency was quantified by densitometry of each band and is indicated below each gel. Results are shown from two
experiments in HeLa and DLD1 cells, each performed in triplicate.
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ated for loss of protein after RBM47 targeting. InWestern blots
one of these clones lacked detectable expression of RBM47 (Fig.
5C). In a similar experiment with HepG2 cells, targeting A1CF,
among seven clones, five appeared to lack A1CF protein (Fig. 5C).
One advantage of the two-step method is that the surrogate
and endogenous targets can be subjected to repeat CRISPR/
Cas9 mutagenesis via subsequent additional transfections of
RGEN components. Puromycin-resistant DLD1 cells contain-
ing theNFE2L2 transposon were transfected twice with RGEN
nickase components specific for this NFE2L2 target site and
then selected with hygromycin. Among 51 hygromycin-resist-
ant clones, 43were identified asmutant byT7E1 assay (Fig. 5D).
Thus, with the hygromycin SRIRACCHA reporter, a very high
frequency of mutagenesis can be attained.
SRIRACCHA enables the enrichment of knock-in alleles with a
single-stranded oligodeoxynucleotide (ssODN) donor
Next we determined the enhancement of HDR using
SRIRACCHA and an ssODN donor for insertion of a myristoy-
lation signal at the AKT locus (Fig. 5E). In HeLa cells we pur-
Figure 4. Enrichment of mutant cells with a target transposon conferring hygromycin resistance. A, schematic of HDR of an integrated Piggybac target
transposonwith ahygromycin resistance cassette.B, using thehygromycin reporter for SRIRACCHAwithCas9D10A inDLD1 cells against targets inA1CF,RBM47,
andNFE2L2. The assayworkflow is shownon the left. The bar graph on the right shows the number of surviving colonies after 7 days of hygromycin selection for
targeting gRNAs and a nonspecific (NS) gRNA. C–E, T7E1 assay to analyze mutation rate in DLD1 cells after puromycin or hygromycin selection reveals that
hygromycinenriches formutations in theA1CF (C),RBM47 (D), andNFE2L2 (E) genes. F, two-step transfectionapproachusing theBII-C3H transposoncontaining
the Pten-T1 target site for Ptenmutagenesis in NIH3T3 and IEC6 cells.G, T7E1 assay formutations in themouse Pten gene after selection of transfected NIH3T3
with hygromycin and/or puromycin after mutagenesis with Pten-T1 gRNAs (or NS gRNAs) using the paired nickase approach and Cas9D10A. H, T7E1 assay for
mutations in the rat Ptengene following selection of IEC6, as described inG. Indel frequency (% Indel) is calculated fromband intensity of fragments generated
from T7E1 cleavage.
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sued a one-step transfection of all components as we found that
this cell line transfects with high efficiency. In this approach we
used a target transposon that confers blasticidin resistance and,
after donor repair, hygromycin resistance. InHeLa cells, hygro-
mycin selection enriches for the myrAKT knock-in allele
3-fold (Fig. 5F), as assayed by Taqman QPCR. In a two-step
approach in DLD1 cells, hygromycin selection enriches for the
myrAKT knock-in allele300-fold (Fig. 5G). Although transfec-
tion efficiency will invariably affect mutagenesis, SRIRACCHA
consistently enriches for indels (through NHEJ) or knock-ins
(through HDR) as desired.
Removal of the integrated target transposon
The Piggybac transposon reporter permits removal of the
reporter from the genome using the “excision-only” mutant
transposase PBaseExc Int (or PBex) (Fig. 6A). FACS sorted
GFPHeLa or DLD1 cells were transfected with the PBex plas-
mid or a control plasmid. Subsequently, GFP and RFP intensity
was analyzed every 24 h starting 2 days after transfection. Over
the 10 days after transfection of PBex, GFP intensity in trans-
fected HeLa and DLD1 cells gradually decreased to 40–50%
relative to that of control-transfected cells (Fig. 6, B and C),
indicating that PBex triggered the successful removal of the
transposon reporter from the genome.
Discussion
We have established a new approach for gene editing using
the PiggybacDNA transposon as a surrogate RGEN reporter in
ourSRIRACCHAmethod,whichpermits theefficientmeasure-
ment of nuclease activity and long term enrichment of targeted
Figure5.Enriching fornull andknock-inalleleswithSRIRACCHA.A,modifiedworkflow for2-step transfectionandhygromycinSRIRACCHAassay.B, images
of hygromycin-resistant DLD1 colonies in 6-well plates for targeting gRNAs and a nonspecific (NS) gRNA. C, upper blot, Western blots to detect RBM47
expression in parental (P, untreated) and hygromycin-resistant DLD1 clones after undergoing SRIRACCHA with the hygromycin vector. C, lower blot, Western
blots to detect A1CF expression in 7 HepG2 clones, also after undergoing SRIRACCHA with the hygromycin vector. A total of 20 HepG2 clones were assessed
for A1CF expression by Western blot, with 12 clones showing loss of A1CF (not shown). In both cases DLD1 and HepG2 cells were subjected to the two-step
transfectionmethod (as inA). Results are from three experimentswith the two-stepmethod (B andC).D, T7E1 assay to analyzemutation rate ofNFE2L2 inDLD1
clones subjected to two-stephygromycin SRIRACCHAwith gRNAs targetingNFE2L2. Controls NS1, NS2, andpositive control (Pos.) are pools of cells transfected
with the indicated target transposons or gRNAs. Themajority (84%) of clones aremutated at the endogenousNFE2L2 target site. E, schematic for targetingAKT
with Cas9N and a ssODN for generating an AKT allele with amyristoylation signal at the amino terminus. Successful targetingwas quantified by TaqmanQPCR
using primers flanking the target site and a fluorescent probe nested within the myristoylation sequence. F, Taqman results for QPCR of the myristoylation
sequence in AKT after a one-step SRIRACCHA transfection using the paired nickase approach in HeLa cells. G, Taqman QPCR results for the myristoylation
sequence following a two-step SRIRACCHA transfection using the paired nickase approach in DLD1 cells. Taqman QPCR levels were normalized to total
AKT signal from a separate EvaGreen QPCR reaction using the indicated primers in E. Error bars represent S.E. of an experiment performed in triplicate, where
Student’s t test was performed to evaluate significance, with p values indicated.
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cells. The robust and novel nature of SRIRACCHA stems from
stable expression conferred after the highly efficient mobiliza-
tion and integration of the Piggybac reporter into the host
genome. For single transfection approaches to assay RGEN
nuclease activity, the use of Piggybac greatly amplifies and sus-
tains the signal obtained from theH2B-GFP reporter. Our stag-
gered (two-step) transfection procedure (in which the Piggybac
reporter is first mobilized into the genome before introduction
of RGENs and donor plasmids) permits the measurement of
nuclease activity at the surrogate target site exclusively in the
context of the host genome. This is likely more representative
of native genomic targets, in contrast to episomal reporters (in
which chromatin proteins are likely absent), and we speculate
that SRIRACCHA may yield a more accurate characterization
of RGEN activity in vivo.
Multiple examples of episomal surrogate reporters have been
previously described for mutation enrichment after genome
manipulation with site-specific nucleases (41–44, 46, 47).
These reporters provide a read-out of DNA repair via theNHEJ
or single-strand annealing pathways. In the case of NHEJ
reporters, a deletion will yield expression of a fluorescent pro-
tein if the deletion restores the reading frame. This low level
yield per deletion could account for the relatively poor sensitiv-
ity of theNHEJ-based reporters (47).Of note, all of the episomal
reporters share one limitation: they rely on plasmidDNA trans-
fected into cells where it exists transiently as an extra-chromo-
somal fragment. The use of transient episomal DNA likely lim-
its the utility of such surrogate reporter assays to cell lines that
can be transfected with high efficiency, such as HEK293 cells, a
cell type frequently used for demonstrating the efficacy of epi-
somal reporters (41–44). Furthermore, transient episomal
reporters that confer resistance to antibiotics such as hygromy-
cin or puromycin are cumbersome for achieving optimal
enrichment of modified cells before loss of the episomal vector;
the timing and efficacy of such selection is dubious because the
precise moment of episomal loss is unpredictable, which com-
plicates antibiotic treatments that require3–4 days of selec-
tion. Long term and complete antibiotic selection with epi-
somal reporters is thus unreliable and simply not tenable for
most cell lines because of the limitations of transfection effi-
ciency and the temporary nature of episomal expression.
In addition to other advantages, SRIRACCHA provides an
unmet need for an HDR reporter. The use of an HDR reporter
also ensures that mutagenesis occurs in dividing cells, consid-
ering that HDR occurs only in cells undergoing DNA synthesis
(48). Thus, for the enrichment and propagation of mutants,
selecting against non-dividing cells with an HDR reporter may
help select clones capable of expansion, which is necessary for
genotyping and phenotypic characterization. Although NHEJ
reporters may provide greater signal (despite missing deletions
that do not restore the reading frame of the reporter), our HDR
reporter provides a robust read-out with the key advantage that
SRIRACCHA enriches for both NHEJ and HDR events. This is
not surprising as NHEJ is the dominant repair pathway of dou-
ble-strand breaks (49) and is likely frequent in cells undergoing
HDR.
We envision the greatest utility of our Piggybac-based
SRIRACCHAmethod lies in the ability to enrich mutated cells.
Stable expression enables long term enrichment of clones
expressing H2B-GFP or the hygromycin resistance gene. This
selection in turn enriches for clones with mutations at the
endogenous target sites in the host genome. Although the level
of enrichment varies (from 1.5–3.5-fold by T7E1 assay), this
differential may be linked to the efficiency of targeting gRNAs;
i.e. poorer gRNAs benefit more than those of higher efficiency
(Fig. 4, B–E). T7E1 assays of hygromycin-selected cells indicate
that A1CF targeting benefits the most from enrichment with
the surrogate reporter, whereas RBM47 appears to benefit the
least (Fig. 4,C–E). This phenomenonmay indicate that the high
level enrichment (e.g. up to 35-fold) of mutated cells seen with
Cas9 episomal surrogate reporters (42, 43) could be predicated
on lower gRNA/RGEN efficiency as previously noted (42). On
the other hand, studies using episomal surrogates of NHEJ and
single-strand annealing also report modest enrichment (2–3-
fold, by T7E1) (47). In the former studies (42, 43) assays were
performed in HEK293 and HeLa cells, whereas assays in the
latter used porcine embryonic fibroblasts (47). These different
cell typesmay also account for differences in enrichment. How-
ever, some studies in HEK293 also report lower enrichment
(1.9–3-fold) using NHEJ reporters (44), so nuclease efficiency
may play a greater role in dictating -fold enhancement.
Figure 6. The target transposon is removable with the excision-only PB transposase. A, schematic showing mobilization of the H2B-GFP target trans-
poson (afterHDR)by theexcision-onlyPiggybac transposase (PBaseExcInt) and subsequentdegradation to yieldGFP-negative cells.B,meanGFP intensityper
RFP cell at 10 days post-transfection in GFP-sorted HeLa or GFP-sorted DLD1 cells transfected with pCMV-PBaseExcInt or a negative control vector (pCMV-
Luc) together with an RFP vector (pCMV-tdT) for normalization. C, mean GFP intensity of cells transfectedwith pCMV-PBaseExcInt relative to GFP intensity of
cells transfectedwith a negative control vector (pCMV-Luc) starting 2 days after transfection. GFP signal was only quantified in cells that are RFP-positive. Error
bars represent S.E. of an experiment performed in triplicate, where Student’s t test was performed to evaluate significance, with p 0.05 (*).
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In contrast to previous descriptions of episomal surrogate
reporters for site-specific nucleases (41–44, 46, 47), our gRNAs
were either preselected for optimal activity (against NFE2L2
and Pten) before assays of mutation enrichment or we com-
pared enrichment after adjusting for transfection efficiency (e.g.
Hygro-resistant versus Puro-resistant cells in Fig. 4, C–E).
Thus, our “baseline”may be higher because of this prescreening
or normalization. Consistent with this, we always detect muta-
tions by T7E1 assays in mutated cells, whereas previous
descriptions of episomal reporters often could not detectmuta-
tions in unselected cells (41, 43, 46). In such instanceswhere the
mutation load in unselected cells is undetectable by T7E1 assay
(41, 43, 46), the -fold changes were calculated to be quite high,
based on a denominator that is estimated (i.e. a mutation fre-
quency of 0.5–1%). However, recent deep sequencing andT7E1
assays we performed using wild type Cas9 indicated that T7E1
does not detect a mutation frequency below 3% (data not
shown), a level similar to previous reports (44). Thus, underes-
timatedmutation frequencies in controlsmay underlie the high
levels of mutation enrichment seen with other surrogate
reporters.
Regardless, selection and enrichment using SRIRACCHA
may be particularly valuable in situations where a precise loca-
tion of nuclease cleavage is needed (to mutate a particular
codon, e.g.), in which case only one (or a few) target site(s) may
be available, such as the case where we knock-in a myristoyla-
tion signal at the start codon of AKT. For achieving knockouts,
our final numbers are also encouraging; we achieved a very high
mutation rate of NFE2L2 in DLD1 cells, where we found that
the majority (84%) of clones were mutant by T7E1 assay (Fig.
4H). For targeted mutagenesis of A1CF and RBM47, we also
obtained 13 apparent knockouts among 32 clones examined by
Western blot. Thus, highmutation rates can be readily achieved
with SRIRACCHA. After the characterization of individual
mutant clones using SRIRACCHA, the Piggybac transposon
reporter can be removed with the integration-defective PB
transposase (PBaseExcInt). Sorting for H2B-GFP-negative
cells enables selection of cells that have lost the transposon
reporter after mobilization by the PB transposase. Alterna-
tively, we have also developed a negative selection vector using
HSV-TK (used in Fig. 5, F and G) to select cells resistant to the
anti-viral drug ganciclovir. Removal of the Piggybac reporter
may be critical for reversing any mutagenic effects of the inte-
grated transposon or for restoring puromycin/hygromycin sen-
sitivity or eliminating H2B-GFP fluorescence if desired. Previ-
ous studies have documented that the removal of the Piggybac
DNA transposon results in clean, scar-less restoration of the
genomic integration site in 99% of cases (28, 31–34). This
footprint-free quality of the Piggybac transposon coupled with
the unique availability of both hyperactive (25) and integration
defective PB transposases (30) clearlymakes thePiggybac trans-
poson a superior tool for implementation of SRIRACCHA.
Alternatively, retroviral vectors are commonly used for
CRISPR/Cas delivery (14, 50–53) but are highly mutagenic
because of their preferential insertion in transcriptional units
(54–58) and cannot be easily removed from the genome. Thus,
the use of high fidelity CRISPR systems, such as the Cas9
paired nickase (3, 5) or enhanced-specificity Cas9 mutants
(59, 60), in conjunction with the Piggybac DNA transposon
for surrogate-based enrichment is optimal for minimizing
unintended mutations.
Using thehighly efficientPiggybac transposase, theSRIRACCHA
method works well in many cell types, including seven trans-
formed, non-transformed, and non-immortalized cell lines
used here: HeLa, HEK293T, DLD1, SW480, HepG2, NIH3T3,
and IEC6 cells. This was accomplished using commercial re-
agents without extensive optimization of transfection condi-
tions (see “Experimental procedures”). Transfection efficiency
of cell lines is undoubtedly a limitation of any in vitromutagen-
esis approach, but here we demonstrate that SRIRACCHA is
able to enrich for mutations in cell lines that are easily trans-
fected (such as HeLa) and in cell lines that are inefficiently
transfected (such as IEC6). Many cultured cell lines should be
amenable to the Piggybac-based SRIRACCHA method, pro-
vided that cells possess a functional HDR repair pathway. This
method should prove valuable formanipulation ofmany cell lines
and potentially aid in the development of ex vivomanipulated pri-
mary cells for therapeutic purposes. In sum, SRIRACCHA pro-
vides a robust andpowerful approach for enhancingandenriching
nuclease-mediatedmutagenesis events in cultured cells.
Experimental procedures
Plasmid constructs
The pBS-U6-gRNA plasmid was constructed by PCR-ampli-
fying the U6-gRNA fragment from the pX335 plasmid and
cloning it into the EcoRV site of the pBluescript II KS() vector
(pBSII) (Stratagene). Subsequent cloning into this vector was
accomplished via ligation of double-stranded oligos into the
BbsI sites by standard molecular cloning techniques. The
pX335(D10A) plasmid was a gift from Dr. Feng Zhang (Add-
gene plasmid #42335) (7). Oligos for gRNA cloning are listed in
Table 1. Vectors generated and described here specifically for
SRIRACCHA (PB transposon target vectors, gRNA vectors,
and donor templates) are schematically depicted in Fig. 7.
To construct the BII-CPspaH2B (GFP reporter), BII-CPspaH
(hygromycin reporter), BII-CPspaHTK (hygromycin IRES thy-
midine kinase reporter), and BII-B3HTK (blasticidin-pA-hy-
gromycin IRES thymidine kinase reporter) target vectors, two
copies of the 240-bp core insulator from the chicken -globin
HSIV were cloned between the XbaI and EcoRI sites of the
pXL-BacII vector to generate the pXL-BII-2xInsul vector. An
expression cassette consisting of the CMV promoter, the puro-
mycin resistance gene, a 48-bp HSV thymidine kinase poly-
adenylation (TKpA) signal, the H2B-GFP open reading frame
(lacking an ATG), and an SV40 polyadenylation signal were
cloned between the EcoRV and XbaI sites of the pXL-BII-2xInsul
vector to generate the BII-CPspaH2B vector. The H2B-GFP
sequence in the BII-CPspaH2B vector was replaced with the
hygromycin resistance gene (lacking an ATG) to create the BII-
CPspaH vector. To generate the BII-CPspaHTK vector, an
IRES-HSV-TK (i.e. the thymidine kinase gene from the Herpes
simplex virus) sequence was inserted between the hygromycin
resistance gene and the SV40 polyadenylation signal in the BII-
CPspaH vector. The BII-B3HTK vector is similar to the BII-
CPspaHTK vector but confers blasticidin resistance and is
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driven by theCMVenhancer and hEF1 promoter frompCpG-
free (Invivogen Inc.). Target sequences (generated as double
stranded oligonucleotides, listed in Table 2) were cloned into a
unique BstEII site located between the puromycin (or blastici-
din) resistance gene and the TKpA in all of these target vectors
(BII-CPspaH2B, BII-CPspaH, or BII-CPspaHTK).
The donor vectors were constructed by first cloning a cas-
sette consisting of the puromycin resistance gene, a T2A pep-
tide sequence, followed by the H2B-GFP sequence between the
HindIII and SpeI sites in the pBSII vector (Stratagene) to create
the pBS-PtH2B vector. The pBS-PtH vector was generated
by replacing the H2B-GFP sequence in pBS-PtH2B with the
hygromycin resistance gene. The pBS-PtH2B donor vector is
used in conjunction with the BII-CPspaH2B vector, whereas
the pBS-PtHdonor is used in conjunctionwith vectors contain-
ing puromycin and hygromycin.
For conditional expression of the Cas9 nickase (Cas9D10A), a
lox-stop-lox sequence (LSL) was cloned downstream of the
TRE3G promoter (Clontech) located in the pGIT3G-insul vec-
tor, which was described previously (61). The LSL sequence
consists of loxP sites flanking a splice acceptor from adenovirus
2 (Ad2SA) and four tandem arrayed polyadenylation signals
from mouse Csf3, mouse Prm1, bovine GH1, and rabbit HBB2
genes, in this order. An Ad2SA-TKpA sequence was inserted
upstreamof theTRE3Gpromoter to reduce read-through tran-
scripts and leaky expression. The Cas9D10A sequence from
pX335 was cloned 3 of the LSL sequence to generate the
pGIT3G-LSL-Cas9N vector.
The pCMV-rtTA and pCMV-tdTomato vectors were con-
structed by replacing the -galactosidase sequence in pCMV-
-gal (Stratagene) with the rtTAM2 or tdTomato coding se-
quences. The rtTAM2 and tdTomato sequences were PCR-
amplified from the iiLet7 and Vil-Lin28b-itdT vectors, respec-
tively, which were both described previously (61).
The hyperactive PB transposase (CMV-hyPBase) expression
plasmid was obtained from System Biosciences Inc. (catalog
#PB210PA-1). The expression plasmid (CMV-PBex) encoding
the mutant integration-defective PB transposase (ExcInt)
was also obtained from System Biosciences Inc. (catalog
#PB220PA-1). The pCAG-ERT2CreERT2 vector was a gift from
Connie Cepko (Addgene plasmid #13777) (62). The expression
plasmids hCas9 and hCas9-D10A (hCas9N) were gifts from
George Church (Addgene plasmids #41815 and #41816) (8). All
DNAoligoswere ordered from IDT.All vectorswere verified by
Sanger dideoxy sequencing after cloning with double-stranded
oligos or other double-stranded DNA fragments.
T7E1 assays
Cells from 1 well of a 6-well plate were washed with PBS and
lysed by adding 0.8 ml TNESII buffer (50 mM Tris-HCl, pH 8.0,
100 mM EDTA, 100 mM NaCl, and 1% SDS) and 20 l of 10
mg/ml proteinase K (Roche Applied Science) and incubated at
55 °C overnight. Then, 0.28 ml of saturated NaCl was added to
the lysate and mixed thoroughly on a shaker for 5 min. The
sample was centrifuged at a maximum speed for 10 min, and
0.75 ml of supernatant was then transferred into a new tube.
Genomic DNA was precipitated with 0.5 ml isopropyl alcohol
and washed with 70% ethanol. The DNA pellet was dissolved in
polyamine buffer (10 mM Tris-HCl, pH 8.0, 30 M spermine,
and 70 M spermidine) in the presence of 0.1 mg/ml RNaseA
and incubated at 37 °C for 15 min.
To perform T7E1 assays, gene fragments encompassing the
nuclease target sites were PCR-amplified from genomic DNA
using OneTaq DNA polymerase (New England BioLabs) or
OneTaq Hot Start DNA Polymerase (New England BioLabs)
for 30–35 cycles with 60 s per Kb extension time. Primers used
for PCR are listed in Table 3. Then 5l of the PCR reaction was
annealed and digested with 2 units of T7 endonuclease I (New
England BioLabs) at 37 °C for 15min. Digested DNA fragments
were then separated and analyzed on a 2.3% agarose gel. Muta-
tion frequency from T7E1 assays was quantified by measuring
the total fluorescence of cut fragments relative to uncut band
fluorescence using a Bio-Rad Chemidoc XRS Imaging System.
Enteroid culture and transfection
Mouse enteroid/tumoroid culture and transfection proto-
cols were adapted from methods as previously reported (39).
For regular maintenance, mouse enteroids were grown in 100%
Geltrex matrix (Thermo-Fisher Scientific) or Matrigel (Corn-
ing Inc.) in growthmedium: advancedDMEMmedium supple-
mented with 2mM glutamax (Thermo Fisher Scientific), 10mM
HEPES, 1 penicillin-streptomycin, 50 ng/ml mEGF (R&D
Systems Inc.), 5% Noggin- and Rspo1-conditioned medium, 1
mM N-acetylcysteine, 1 N2 supplement (Thermo Fisher Sci-
entific), and 1 B27 supplement (Thermo Fisher Scientific).
Noggin- and Rspo1-conditioned medium was obtained from
HEK293T cells transduced with a vector containing the mouse
Noggin and Rspo1 open reading frames (ORFs). Similarly,
Wnt3a-conditioned medium was obtained from HEK293T
Table 1
Oligonucleotides for cloning gRNAs
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cells transduced with a vector containing the human Wnt3a
ORF.
To prepare cells for transfection and expand stem cell num-
bers, mouse enteroids were cultured for 3 days in expansion
medium (growth medium plus 10 mM nicotinamide and 50%
Wnt-conditioned medium). Before transfection, stem cell-en-
riched enteroids were mechanically dissociated and incubated
with TrypLE Express (Thermo Fisher Scientific) for 5 min with
periodic vortexing (every minute). Dissociated cells were spun
at 100 g for 2min and resuspended in growthmediumplus 10
Figure 7. Vectors for SRIRACCHA. A–C, PB transposon vectors for insertion of synthetic target sequences containing puromycin resistance cassettes and
H2B-GFP reporters A, puromycin and hygromycin resistance cassettes (B) and blasticidin and hygromycin resistance cassettes (C). Each target has a unique
BstEII site for cloning target sequences. Vectors are driven by either the CMV promoter or the CMVe/EF1 hybrid promoter (C-hEF1a) devoid of CpG dinucle-
otides. Some vectors also contain an IRES-TK module for negative selection. D and E, vectors for gRNA expression, with a single gRNA expression cassette (D)
or dual gRNA expression cassettes (E) with BpiI sites, as indicated, for cloning gRNA sequences. F, lastly, three donor vectors provide a template for HDR after
nuclease cleavage at surrogate target sites.
Table 2
Oligos for generating paired nickase target sites in target transposon vectors
The sense strand of the right target site is shown in bold. The antisense strand of the left target site is underlined.
Target
Target sequence
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mM nicotinamide, 30% Wnt-conditioned medium, and 10 M
Rho kinase inhibitor (Y-27632) (Santa Cruz Biotechnology
Inc.). Then, 450 l of resuspended cells were plated in 1 well of
a 24-well plate before transfection with Lipofectamine 2000
(Thermo Fisher Scientific). A typical transfection reaction was
prepared by mixing 1 g of DNA and 3 l of Lipofectamine
2000 each in 25 l of DMEM, combining these mixtures, and
incubating for 5 min at room temperature. After the transfec-
tion mixture was added to cells, the plate was centrifuged at
600  g for 1 h at 32 °C followed by a 4-h incubation at 37 °C.
Cells were then collected and cultured in 100% Geltrex matrix
(or Matrigel) in the presence of 10 M Y-27632.
Transfection with the SRIRACCHAH2B-GFP reporter
HEK293T, HeLa, and DLD1 cells were cultured in DMEM,
10% FBS, and 1 penicillin-streptomycin. Unless noted other-
wise in individual experiments, cells were transfected as fol-
lows. HEK293T cells were seeded at a density of 30,000 cells/
well of a 24-well plate, andHeLa cells were seeded at a density of
35,000–50,000 cells/well of 48-well plate. The next day cells
were transfected with 250 ng of total DNA of a plasmid mix
consisting of 10 ng of pCMV-tdTomato, 65 ng of pBII-
CPspaH2B, 20 ng of CMV-hyPBase, 39 ng of pBS-PtH2B, 25 ng
of pCMV-rtTA, 40 ng of pGIT3G-LSL-Cas9N, 25 ng of CAGG-
ERT2-CRE-ERT2, and 26 ng of pBS-U6-gRNA using Lipo-
fectamine 2000 (Thermo Fisher Scientific) with a Lipofect-
amine:DNA ratio of 3:1. Twenty-four hours after transfec-
tion, medium was replaced with fresh medium containing 0.5
g/ml dox (Sigma) and 1 M 4-OH-T (Sigma). GFP fluores-
cence was analyzed 72 h after the addition of doxycycline and
4-OH-T. For transfection of wild-type Cas9 in HeLa cells, 225
ng of total DNA consisting of 10 ng of pCMV-tdTomato, 39 ng
of pBS-PtH2B, 65 ng of pBII-CPspaH2B, 20 ng of CMV-hy-
PBase, 65 ng of hCas9, and 26 ng of pBS-U6-gRNA were trans-
fected into each well using JetPrime transfection reagent
(Polyplus) according tomanufacturer’s instruction at a 2:1 ratio
(JetPrime:DNA). GFP fluorescence was then examined 72 h
after transfection. GFP and RFP fluorescence was analyzed on a
Cytation3 (Biotek) and quantified using Gen5 software. The
number of GFP cells was normalized to the number of RFP
cells.
Suitable gRNAs against NFE2L2 were first selected among
four gRNA pairs after screening for double-strand breaks
induced by Cas9D10A in HEK293T cells (not shown). To obtain
DLD1 or HeLa cells with stable integration of the BII-
CPspaH2B Piggybac reporter for the selected NFE2L2 target
site, DLD1 or HeLa cells were seeded at a density of 4  105
cells/well of a 6-well plate 18 h before transfection. Then, 1.5g
of the BII-CPspaH2Btarget construct and 0.5 g CMV-hy-
PBase were transfected into each well using 8 l of Lipo-
fectamine 2000. To select for transposon reporter integration, 2
g/ml or 5 g/ml puromycin were added to the transfected
HeLa or DLD1 cells, respectively, 48 h post-transfection. The
resulting stable DLD1 and HeLa cell lines (containing the BII-
CPspaH2B reporter with theNFE2L2 target site) were used for
subsequent CRISPR assays. In these H2B-GFP SRIRACCHA
assays each cell line was transfected as described above for
HeLa cells except that the BII-CPspaH2B and CMV-hyPBase
plasmidswere excluded from the transfectionmixture. HeLa or
DLD1 cells (containing the reporter) from 1 well of a 48-well
plate were transferred to one well of a 6-well plate and cultured
until confluent. Cells were then sorted to purify H2B-GFP-pos-
itive cells using a FACSAria II cell sorter (BD Biosciences).
Sorted GFPHeLa or DLD1 cells were cultured, and their gen-
otype was then analyzed by T7E1 assay. In experiments testing
for transposon removal with the integration defective PB trans-
posase (ExcInt), H2B-GFP-positive DLD1 or HeLa cells
were expanded and plated at a density of 50,000 cells per well of
a 24-well plate 18 h before transfection. Then, 450 ng of pCMV-
Luc or pCMV-PBex along with 50 ng pCMV-tdTomato were
co-transfected into each well using 2 l of Lipofectamine 2000.
Using the Cytation3 and Gen5 Software (Biotek), GFP and RFP
fluorescence were quantified every 24 h starting at 48 h post-
transfection. To evaluate the efficiency of transposon removal
using the integration defective PB transposase (ExcInt), the
GFP intensity of cells that were successfully transfected (and
RFP-positive) was quantified.
Comparison of Cas9WT and Cas9D10A NHEJ frequencies by
deep sequencing
Mouse N2A cells were nucleofected with equal amounts of
GFP or a site-specific gRNA and Cas9/Cas9D10A expression
plasmid using the Lonza 4D nucleofector with 16-well Nucle-
ocuvette Strips and Lonza published parameters. Three days
post nucleofection, N2A cells were harvested, crude lysates
were prepared, and PCRs were performed for the NHEJ analy-
sis. PCRs were performed using Illumina protocols and primer
sequences to add a barcode and adapters to PCR amplicons.
Amplicons were sequenced on an Illumina MiSeq. Indel fre-
quencies were calculated by comparison ofMiSeq sample reads
to the corresponding NCBI reference sequence. Samples were
normalized to sequence reads fromGFP transfected controls to
correct for sequencing errors.
Transfection with the SRIRACCHA hygromycin reporter
For one-step transfectionDLD1 cells were plated at a density
of 5 105 cells per well of a 6-well plate for assaying the Piggybac
hygromycin reporter (BII-CPspaH) containing target sites for
A1CF, RBM47, or NFE2L2. Cells were transfected 18 h later
with 290 ng of hCas9N, 290 ng of BII-CPspaH, 170 ng of pBS-
PtH, 120 ng of pBS-gRNA (targeting or nonspecific), 90 ng of
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pCMV-hyPBase, and 40 ng of pCMV-tdTomato using 4 l of
Lipofectamine 2000 (Life Technologies). After 48 h cells were
split 1:2 into an identical 6-well plate, and either puromycin (5
g/ml) or hygromycin (600 g/ml) was added to each plate.
After 7 days of selection, hygromycin-resistant colonies were
quantified. Twelve hygromycin-resistant colonies targeted at
RBM47 were picked, expanded, and characterized for RBM47
protein expression by Western blot. For the remaining colo-
nies, after 12 days of selection both hygromycin- and puromy-
cin-resistant cells were pooled and harvested for isolating
genomic DNA for T7E1 assays.
For two-step transfection of DLD1, cells were plated as
above, then transfected with 0.5g pCMV-hyPBase and 1.5g
of the Piggybac hygromycin reporter (BII-CPspaH) containing
target sites for either A1CF, RBM47, or NFE2L2 genes using 8
l of Lipofectamine 2000. After 24 h, cells were split 1:2 into 2
wells of a 6-well plate. After 48 h, 5 g/ml puromycin was
added, and cells were selected for 72 h. Cells were then trans-
fected with 1 g of hCas9N, 0.6 g of pBS-PtH, and 0.4 g of
pBS-gRNA (targeting or nonspecific). Cells were selected for 7
days, stained with methylene blue, and photographed.
For two-step transfection of NIH3T3 cells and IEC6 cells
50,000 cells were seeded into 1 well of a 12-well plate and then
transfected the next daywith 200 ng of pCMV-hyPBase and 800
ng of BII-C3H-PtenT1 vector. NIH3T3 were transfected using
3l of JetPrime (Polyplus), whereas IEC6were transfectedwith
3l of Lipofectamine 2000 per themanufacturer’s instructions.
After 48 h cells were selected with puromycin for 5 days
(NIH3T3, 2 g/ml) or for 7 days (IEC6, 4 g/ml). These
selected cells were then seeded in 6-well plates at a density of
3 105 cells per well and transfected the following day with 1.0
g of hCas9N, 600 ng of pBS-PtH, and 400 ng of pBS-
U6gRNAx2 (PtenT1 or nonspecific gRNAs) with the transfec-
tion reagents above. After 48 h, hygromycin was added, and
cells were selected for 3 days (NIH3T3, 400 g/ml) or 7 days
(IEC6, 100 g/ml), then expanded for 7 days before isolation of
gDNA. PCR and T7E1 assays were performed as described
above, using Pten_T1_F and Pten_T1_R2 primers (see Table 3).
For characterization of individual NFE2L2-targeted DLD1
clones, 4 105 cells were plated and transfected 18 h later using
7.5 l of Lipofectamine 2000 with 0.5 g of pCMV-hyPBase
and 2 g of the Piggybac hygromycin-TK reporter (BII-CP-
spaHTK) containing no target site or a target site for NFE2L2.
After 48 h 5 g/ml puromycin was added, and cells were
selected for 5 days. Cells were split between 2 wells of a 6-well
plate and transfected after 18 h with 1 g of hCas9N, 0.6 g of
pBS-PtH, and 0.4 g of pBS-gRNA (targeting or nonspecific)
using 4 l of JetPrime reagent (Polyplus). After 48 h the trans-
fection of CRISPR components and the donor vector was
repeated. After 48 h of this second transfection, one-half of the
cells were split into one 10-cm plate and selected with 600
g/ml hygromycin for 10 days. Individual hygromycin-resist-
ant colonies were then picked and expanded for isolating
genomic DNA for T7E1 assays.
For targeting AKT in HeLa cells for knock-in of a myristoy-
lation signal, 7.5  105 cells were seeded and transfected the
next day with 30 pmol of myrAKT ssODN, 500 ng of hCas9N,
450 ng of BII-B3HTK-AKT, 250 ng of pBS-BtH, 170 ng of pBS-
U6gRNAx2, and 130 ng of pCMV-hyPBase using 5 l of
JetPrime (Polyplus) per themanufacturer’s instructions. Anon-
specific ssODN (MTOR_S2215Y) was used as a control. Oligo
donors andQPCRprimers are listed in Table 4. 48 h after trans-
fection cells were selected with either blasticidin (8 g/ml) or
hygromycin (400 g/ml) for 9 days, and then gDNA was iso-
lated for TaqmanQPCR using 50 ng of DNAper 20-l reaction
using the iTaqUniversal ProbesMastermix (Bio-Rad). Levels of
myrAKT were normalized to endogenous AKT levels with
AKT_990(F) and AKT_1146(R) primers (Table 3) using the
SsoFast EvaGreen Supermix (Bio-Rad).
For targeting AKT in DLD1, cells were first transfected with
pCMV-hyPBase and BII-B3HTK-AKT as described above for
the first part of the two-step transfection method. After 5 days
of selectionwith 5g/ml blasticidin, 7.5 105 cellswere seeded
and transfected the next day with 30 pmol of myrAKT ssODN,
500 ng of hCas9N, 300 ng of pBS-BtH, and 200 ng of pBS-
U6gRNAx2 using 4 l of JetPrime (Polyplus) per the manufa-
cturer’s instructions. 48 h following transfection cells were
selected with hygromycin (600 g/ml) for 12 days and
expanded for 3 additional days, and then gDNAwas isolated for
QPCR as described above for HeLa cells.
The human hepatocellular carcinoma cell line, HepG2, was
transfected with a total of 1 g of plasmid mix containing 750
ng of BII-CPspaH-A1CF target vector and 250 ng of pCMV-
hyPBase using 3 l of X-tremeGENE 9 DNA transfection
(RocheApplied Science). Two days after transfection cells were
placed under puromycin selection (5g/ml) for 1 week. Surviv-
ing cells were transfected with 1 g of plasmid mix containing
500 ng of hCas9N, 200 ng of pBS-A1CF gRNA, and 300 ng of
pBS-PtH. After 48 h, cells were expanded in a 100-mm dish.
After five rounds of transfection of CRISPR/Cas9 components,
cells were placed under hygromycin selection (600 g/ml).
Individual resistant colonieswere picked and expanded for pro-
Table 4
Oligos and primers used for targeting AKT
*, phosphorothioate linkage.








Negative control (non-specific) donor oligo
PAGE-purified
AKT_990 (F) CTTCCTTTGCTTCTCCCAGAG QPCR (SYBR or Taqman) with AKT_1146(R)
AKT_1146 (R) CTCGTTTGTGCAGCCAAC QPCR (SYBR or Taqman) with AKT_990(R)
AKT_probe GAGCAGCAAGAGCAAGCCCAAG Taqman probe for QPCR with AKT_990(F)
and AKT_1146(R)
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tein expression analysis. Of the 20 clones analyzed 12 showed
a97% decreased A1CF expression.
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